-
Something wrong with this record ?
Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice
O. Horakova, D. Medrikova, EM. van Schothorst, A. Bunschoten, P. Flachs, V. Kus, O. Kuda, K. Bardova, P. Janovska, M. Hensler, M. Rossmeisl, R. Wang-Sattler, C. Prehn, J. Adamski, T. Illig, J. Keijer, J. Kopecky,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Diet, High-Fat adverse effects MeSH
- Glycolysis drug effects MeSH
- Muscle Fibers, Skeletal drug effects metabolism MeSH
- Muscle, Skeletal drug effects metabolism MeSH
- Metabolomics MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Obesity etiology metabolism MeSH
- Fatty Acids, Omega-3 pharmacology MeSH
- Oxidation-Reduction drug effects MeSH
- Gene Expression Regulation drug effects MeSH
- Drug Synergism MeSH
- Thiazolidinediones pharmacology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Insulin resistance, the key defect in type 2 diabetes (T2D), is associated with a low capacity to adapt fuel oxidation to fuel availability, i.e., metabolic inflexibility. This, in turn, contributes to a further damage of insulin signaling. Effectiveness of T2D treatment depends in large part on the improvement of insulin sensitivity and metabolic adaptability of the muscle, the main site of whole-body glucose utilization. We have shown previously in mice fed an obesogenic high-fat diet that a combined use of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and thiazolidinediones (TZDs), anti-diabetic drugs, preserved metabolic health and synergistically improved muscle insulin sensitivity. We investigated here whether n-3 LC-PUFA could elicit additive beneficial effects on metabolic flexibility when combined with a TZD drug rosiglitazone. Adult male C57BL/6N mice were fed an obesogenic corn oil-based high-fat diet (cHF) for 8 weeks, or randomly assigned to various interventions: cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids (cHF+F), cHF with 10 mg rosiglitazone/kg diet (cHF+ROSI), cHF+F+ROSI, or chow-fed. Indirect calorimetry demonstrated superior preservation of metabolic flexibility to carbohydrates in response to the combined intervention. Metabolomic and gene expression analyses in the muscle suggested distinct and complementary effects of the interventions, with n-3 LC-PUFA supporting complete oxidation of fatty acids in mitochondria and the combination with n-3 LC-PUFA and rosiglitazone augmenting insulin sensitivity by the modulation of branched-chain amino acid metabolism. These beneficial metabolic effects were associated with the activation of the switch between glycolytic and oxidative muscle fibers, especially in the cHF+F+ROSI mice. Our results further support the idea that the combined use of n-3 LC-PUFA and TZDs could improve the efficacy of the therapy of obese and diabetic patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13012481
- 003
- CZ-PrNML
- 005
- 20130408112419.0
- 007
- ta
- 008
- 130404s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0043764 $2 doi
- 035 __
- $a (PubMed)22952760
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Horakova, Olga $u Department of Adipose Tissue Biology, Institute of Physiology Academy of Sciences of the Czech Republic v.v.i., Prague, Czech Republic.
- 245 10
- $a Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice / $c O. Horakova, D. Medrikova, EM. van Schothorst, A. Bunschoten, P. Flachs, V. Kus, O. Kuda, K. Bardova, P. Janovska, M. Hensler, M. Rossmeisl, R. Wang-Sattler, C. Prehn, J. Adamski, T. Illig, J. Keijer, J. Kopecky,
- 520 9_
- $a Insulin resistance, the key defect in type 2 diabetes (T2D), is associated with a low capacity to adapt fuel oxidation to fuel availability, i.e., metabolic inflexibility. This, in turn, contributes to a further damage of insulin signaling. Effectiveness of T2D treatment depends in large part on the improvement of insulin sensitivity and metabolic adaptability of the muscle, the main site of whole-body glucose utilization. We have shown previously in mice fed an obesogenic high-fat diet that a combined use of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and thiazolidinediones (TZDs), anti-diabetic drugs, preserved metabolic health and synergistically improved muscle insulin sensitivity. We investigated here whether n-3 LC-PUFA could elicit additive beneficial effects on metabolic flexibility when combined with a TZD drug rosiglitazone. Adult male C57BL/6N mice were fed an obesogenic corn oil-based high-fat diet (cHF) for 8 weeks, or randomly assigned to various interventions: cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids (cHF+F), cHF with 10 mg rosiglitazone/kg diet (cHF+ROSI), cHF+F+ROSI, or chow-fed. Indirect calorimetry demonstrated superior preservation of metabolic flexibility to carbohydrates in response to the combined intervention. Metabolomic and gene expression analyses in the muscle suggested distinct and complementary effects of the interventions, with n-3 LC-PUFA supporting complete oxidation of fatty acids in mitochondria and the combination with n-3 LC-PUFA and rosiglitazone augmenting insulin sensitivity by the modulation of branched-chain amino acid metabolism. These beneficial metabolic effects were associated with the activation of the switch between glycolytic and oxidative muscle fibers, especially in the cHF+F+ROSI mice. Our results further support the idea that the combined use of n-3 LC-PUFA and TZDs could improve the efficacy of the therapy of obese and diabetic patients.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a dieta s vysokým obsahem tuků $x škodlivé účinky $7 D059305
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a omega-3 mastné kyseliny $x farmakologie $7 D015525
- 650 _2
- $a regulace genové exprese $x účinky léků $7 D005786
- 650 _2
- $a glykolýza $x účinky léků $7 D006019
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolomika $7 D055432
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a kosterní svalová vlákna $x účinky léků $x metabolismus $7 D018485
- 650 _2
- $a kosterní svaly $x účinky léků $x metabolismus $7 D018482
- 650 _2
- $a obezita $x etiologie $x metabolismus $7 D009765
- 650 _2
- $a oxidace-redukce $x účinky léků $7 D010084
- 650 _2
- $a thiazolidindiony $x farmakologie $7 D045162
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Medrikova, Dasa $u -
- 700 1_
- $a van Schothorst, Evert M $u -
- 700 1_
- $a Bunschoten, Annelies $u -
- 700 1_
- $a Flachs, Pavel $u -
- 700 1_
- $a Kus, Vladimir $u -
- 700 1_
- $a Kuda, Ondrej $u -
- 700 1_
- $a Bardova, Kristina $u -
- 700 1_
- $a Janovska, Petra $u -
- 700 1_
- $a Hensler, Michal $u -
- 700 1_
- $a Rossmeisl, Martin $u -
- 700 1_
- $a Wang-Sattler, Rui $u -
- 700 1_
- $a Prehn, Cornelia $u -
- 700 1_
- $a Adamski, Jerzy $u - $7 gn_A_00001616
- 700 1_
- $a Illig, Thomas $u -
- 700 1_
- $a Keijer, Jaap $u -
- 700 1_
- $a Kopecky, Jan $u -
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 7, č. 8 (2012), s. e43764
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22952760 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130404 $b ABA008
- 991 __
- $a 20130408112646 $b ABA008
- 999 __
- $a ok $b bmc $g 975679 $s 810762
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 7 $c 8 $d e43764 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20130404